To reduce fatigue symptoms with the use of a bovine lactoferrin supplement in patients suffering from Long COVID.
ID
Bron
Verkorte titel
Aandoening
Long COVID
Ondersteuning
Onderzoeksproduct en/of interventie
Uitkomstmaten
Primaire uitkomstmaten
- Do fatigue symptoms diminish faster with the use of lactoferrin combined with usual care compared to usual care solely?
Achtergrond van het onderzoek
Rationale: Lactoferrin is an antimicrobial iron-binding glycoprotein that can modulate the immune system and lower oxidative stress levels. Recent evidence indicates a faster recovery from (acute) COVID-19 after using (bovine) lactoferrin supplements. Yet, the effect of lactoferrin in patients suffering from long COVID has not yet been studied. Since immune dysregulation, higher oxidative stress levels and viral persistence could explain at least part of the Long COVID persisting symptoms, including fatigue, muscle weakness, cognitive dysfunction and anxiety and depression, we want to initiate a clinical- and laboratory study looking into the effects of bovine lactoferrin in these patients.
Main objective: To reduce fatigue symptoms with the use of a bovine lactoferrin supplement in patients suffering from Long COVID.
Study design: Investigator-initiated double-blind randomized controlled trial.
Study population: Long COVID patients aged 18-70 years with confirmed COVID-19 (positive RT-PCR or antibody test not older than 9 months).
Intervention (if applicable): Lactoferrin 4 x 300 mg capsules (total 1200 mg) (Bonusan) versus identical placebo capsules; given daily during 6 weeks.
Main study parameters/endpoints: Primary endpoint: Fatigue symptoms (measured with FAS) within 6 weeks and 3 months after initiation of intervention.
Secondary endpoints: Cognitive function (CFQ), Anxiety and depression (HADS), Inflammatory parameters in blood (e.g. IL-6, hsCRP) and muscle strength (Handgrip strength and 30sec Sit-to-Stand test).
Doel van het onderzoek
To reduce fatigue symptoms with the use of a bovine lactoferrin supplement in patients suffering from Long COVID.
Onderzoeksopzet
baseline, 6 and 12 weeks
Onderzoeksproduct en/of interventie
Lactoferrin 1200 mg/day versus Placebo
Publiek
Wetenschappelijk
Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)
- Persistent or newly developed long COVID symptoms at least 12 weeks post-primary SARS-CoV-2 infection
- Patients with a positive COVID-19 RT-PCR- or antibody test not older than 9 months
- Adult patients with age >18 years
Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)
- Patients admitted to the ICU (COVID-19-related)
- COVID-19-related cardiac or pulmonary tissue damage
- Acute infection or current systemic immunological disorders
- Oral and/or inhaled use of corticosteroids or use of other immune-modulatory medication
- Current psychiatric disorders
- Communication difficulties
- Pregnant or lactating women
- Age >70 years
- Patients with milk allergy or a known or suspected allergy or any contraindications to lactoferrin or microcrystalline cellulose (lactoferrin can be used by individuals with lactose intolerance)
Opzet
Deelname
Voornemen beschikbaar stellen Individuele Patiënten Data (IPD)
Opgevolgd door onderstaande (mogelijk meer actuele) registratie
Geen registraties gevonden.
Andere (mogelijk minder actuele) registraties in dit register
Geen registraties gevonden.
In overige registers
| Register | ID |
|---|---|
| NTR-new | NL9742 |
| Ander register | MEC-U : MEC-U 21.081 |